Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 11 of 11

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Treatment Emergent Adverse Events	Study Day 85	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Overall Response Rate	Study Day 29	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Time to Maximum EQ001serum Concentration, Tmax	Day 337
SECONDARY	Maximum EQ001 Serum Drug Concentration, Cmax	Study Day 337
SECONDARY	Minimum EQ001 Serum Drug Concentration, Cmin	Study Day 337
SECONDARY	Total EQ001 Exposure Across Time, AUC (From Zero to Infinity)	Study Day 337
SECONDARY	Half Life of EQ001, t1/2	Study Day 337
SECONDARY	Volume of Distribution of EQ001, Vd	Study Day 337
SECONDARY	Clearance, Cl	Study Day 337
SECONDARY	Inflammatory Markers	Study Day 337
SECONDARY	CD6 Receptor Expression Levels	Study Day 85	Percent of baseline	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03763318/outcomes